LataMed AI Corp. (OTC: LMED), a healthcare technology company specializing in digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan subsidiary, LATAMEDAI VE, has entered into a memorandum of understanding with FARMASER to develop a customized artificial intelligence and automation platform. The platform is designed to support FARMASER’s current operations and its planned expansion across Venezuela.
Under the memorandum, the parties will collaborate on the design, adaptation, testing, and evaluation of a software platform tailored to FARMASER’s operational requirements. This includes defining technical and operational specifications, adapting the software to pharmacy workflows, and establishing a phased development and testing process. The partnership also contemplates integrating LataMed AI’s CardioAI, PulmoAI, and NeuroAI technologies across FARMASER’s three existing pharmacy locations and up to 15 planned additional locations. These AI-supported platforms are intended to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information, subject to continued development and regulatory approvals.
The proposed platform will include e-commerce, prescription-management, customer-service, inventory-planning, and business-analytics functions. Any prescription-related or AI-supported functionality is designed to assist administrative, operational, and healthcare workflows and will not replace the professional judgment of authorized pharmacists, medical professionals, or other qualified personnel.
The parties are also evaluating an annual software licensing or subscription model for commercial implementation. However, the scope, timing, pricing, and other terms of a commercial deployment have not been finalized and remain subject to successful development, testing, and agreement on commercial terms.
“This memorandum of understanding represents an opportunity to apply our technology within an important part of the healthcare delivery ecosystem,” said Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp. “Pharmacies play a central role in connecting patients with medications, healthcare products, and related services. Our objective is to work with FARMASER to develop a platform that supports its current operations and planned expansion while evaluating the integration of our AI-supported healthcare technologies across its pharmacy network.”
Management believes the proposed collaboration aligns with LataMed AI’s broader strategy of developing an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and other participants. The FARMASER platform represents a potential enterprise application of the Company’s technology beyond its patient-facing telemedicine services. By supporting pharmacy operations, digital commerce, prescription workflows, data analysis, and the potential integration of AI-supported healthcare technologies, LataMed AI intends to develop technology infrastructure that may ultimately be adaptable to the needs of other healthcare organizations throughout Latin America.
The memorandum of understanding establishes a framework for cooperation but does not guarantee successful completion or commercial deployment of the platform, integration of AI technologies, execution of a definitive licensing agreement, opening of additional FARMASER locations, or generation of revenue. The Company will provide additional information regarding development and potential implementation as appropriate.
For additional information, please visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
